Brace Yourself for Impact – in Precision Medicine Implementation

On April 23rd-24th, Vision Zero Cancer/ SIR will be at the Nordic Precision Medicine Forum in Stockholm and organise a workshop on impact assessment frameworks for Precision Medicine implementation. Facilitated by the EFIS Centre, the outcome of the “Brace Yourself for Impact – Impact models for Precision Medicine Implementation” workshop will be the first out of three impact model for ECHoS, the EU Cancer Mission hubs, and serve as a case study and prototype for how communities can self-assess the impact of their efforts in beating cancer. In true spirit of the EU Cancer mission, the workshop draws on diverse expertise- from mission-driven innovation and change in complex systems over impact assessment framework design to how to implement equitable and sustainable precision medicine- and is a co-production of Vision Zero Cancer, ECHoS, PCM4EU, PRIME-ROSE with the generous support of the Precision Medicine Forum!

Nordic Precision Medicine Forum

22-23 April 2024 | Stockholm

Firmly established as the leading Precision Medicine meeting in the Nordic region, since 2016 the conference has brought together the leading experts from government, industry, technology, research, and healthcare to share knowledge and connect. In 2024 these experts in the field of Precision Medicine will come together once more in Stockholm for the Nordic Precision Medicine Forum.


ECHoS (Establishing Cancer Mission Hubs: Networks and Synergies) is a project aiming to ensure the implementation of the Cancer Mission activities in all member states by establishing and developing Cancer Mission Hubs operating at national, regional, and local levels.


Personalised Cancer Medicine for Europe, PCM4EU, is a project under the Europe’s Beating Cancer Plan by EU4Health. PCM4EU is about facilitating implementation of molecular cancer diagnostics for precision oncology, and the consortium consists of partners from altogether 15 countries across Europe.


A European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission. The PRIME-ROSE project builds on a bottom-up, clinician-initiated family of PCM clinical trials which have been particularly successful in bringing up inclusion rates to offer additional lines of treatment and in providing patient benefit.

European Future Innovation System Centre

European Future Innovation System (EFIS) Centre is a not-for-profit (ASBL) policy lab established in December 2014. Their experts have vast experience in all aspects of research and innovation (R&I) policy and ecosystem governance. EFIS challenge the status quo with new policy and practice insights, concepts, methodologies, and analysis. We are committed to helping public sector decision-makers design and implement the R&I systems of the future.

Vision Zero Cancer are proud to be a part of Community 365

Yesterday Ebba Hallersjö Hult met Mike Morrissey, Chief Executive, European Cancer Organisation & President, European Society of Association Executives, at the EU Beating Cancer Plan and the EU Cancer Mission conference and continued our dialogue on how Vision Zero Cancer can contribute to the Focused Topic Network of the European Cancer Organisation.

Community 365 – European Cancer Organisation

Networks of the European Cancer Organisation. Community 365 provide ideas, guidance, practical support and resources for our work in convening stakeholders and building consensus in the European cancer community.

Policies of the European Cancer Organisation are agreed by our Board after consultation with our Member Societies and Patient Advisory Committee. Community 365 contributors do not have a decision-making role in our policy work. Read more about our policy approval pathway here.   Community 365 also has additional not-for-profit organisations as supporters of our Mission & VisionStrategy and Focused Topic Networks.

Vision Zero Cancer & OECD OPSI: workshop on mission driven innovation around personalised medicine

On 7–8th of October, Vision Zero Cancer together with OECD Observatory of Public Sector Innovation met together with around 60 participants, speakers, and panellists for a Mission-oriented Innovation Bootcamp – a journey into the intersection of mission-oriented innovation and personalised medicine. The purpose of the workshop was to introduce the concept mission-oriented innovation and how to use it for working together to make personalised medicine available for all cancer patients.

The focus of the two-day bootcamp: A journey into the crossing of mission-oriented innovation and personalised medicine, was to introduce the concept, collecting perspectives on how to make the mission come to life, to decide who needs to do what and share how to activate the ecosystem and synergies across different innovations. In the digital workshop, the participants had the opportunity to ask questions, work together and learn from speakers who transparently shared their experiences and hinderances on the topic.

Ebba Hallersjö Hult, head of Vision Zero Cancer, highlighted how important it is to involve the whole healthcare system. OECD and UCL IIPP showed that shared missions with combined strategy, coordination, and implementation to tackle global complex challenges works and pointed to the example of developing a global vaccine for Covid-19.

Many international examples where shared. Health Holland are working on a mission for better dementia care, where an important mechanism has been to connect the overall mission with the work in so called Field Labs. Germany’s mission-oriented work with their Decade against cancer is a valuable example of taking a more patient-centred approach through webinars, events, and panels to include the public. The UK, Camden borough, is working on a mission for combatting child poverty demonstrating a central mapping tool for getting the big picture of all the activities that needs to happen simultaneously to achieve a mission. Australia’s work on Genomics Health Futures mission showed success factors in setting up inclusive expert panels to set the mission and its implementation. Together this went to show how important it is to try different ways of working towards missions and sharing experiences along the way, across sectors and between different areas of societal challenges. 

The importance of communication and trust was addressed and highlighted during the panel discussion. The panel also discussed the value of working in different partnership models and broadening the perspectives with unusual players, always factoring in the individuals behind the topics discussed and that human behaviour is one of the crucial factors determining if we move towards the mission.

– The pandemic has tested the healthcare system around the world but has also created an opportunity to redefine cancer care. We are not going back to the past. We are going to add a new normal and it is a great opportunity to define that new normal together, says Ebba Hallersjö Hult.

In February 2021, the European Commission presented Europe’s Beating Cancer Plan. With new technologies, research and innovation as the starting point, the Cancer Plan sets out a new EU approach to cancer prevention, treatment, and care. Personalised Medicine represents a paradigm shift in health and requires the coordinated action of multiple stakeholders. Vision Zero Cancer believes that a Mission-based approach can be successfully applied to the implementation of personalised medicine and the outcome of workshops held during the bootcamp renders this belief.

We look forward to further exchanging valuable lessons on how missions can tackle wide societal challenges in innovative ways and to collaborate across sectors to achieve a transformation around cancer so that it is eliminated as a life-threatening disease for future generations, working towards the vision that no one should die from cancer and more people should live longer and better.


The team co-hosting the event together with Vision Zero Cancer: OECD Observatory of Public Sector Innovation (OPSI). Chiara Bleckenwegner, Angela Hanson, Piret Tõnurist, Philippe Larrue, Rebecca Santos, Luca Kuhn von Burgsdorff and Davide Albeggiani.

Sharing mission-cases: Elspeth Langford and Saraid Billiards with the Genomics Health Futures Mission, Hubert Misslisch with The National Decade against Cancer, Kirsten van Spronsen from Health-Holland and Weronica Sarnowska with Camden Council.

Panelists: Anders Brinne (Vinnova), Bernd Stowasser, Bettina Ryll (Melanoma Patient Network Europe), Hans Hägglund (Regionalt cancercentrum), Henry L. Li (UCL Institute for Innovation and Public Purpose), Richard Rosenquist Brandell (Genomic Medicine Sweden), Suzanne Håkansson (Astra Zeneca), Terje Peetso (The North Estonia Medical Centre) and Ulrik Ringborg (The European Academy of Cancer Sciences).

A lot of cancer is preventable

A third of all cancer depend on living habits. This means that one third of all cancers are preventable. And if fewer people get sick, we reduce people’s suffering, increase public health and save society’s resources. The only question is how.

Follow link

This is Vision Zero Cancer

Vision Zero Cancer challenges the prevailing ecosystem and connects new ones. We are going to turn cancer from a deadly into a curable or chronic disease.

Who we are
Follow link

Knowledge and experience exchange with Sweden: Early detection of lung cancer in never-smokers

Lung cancer accounts for one in five deaths worldwide. The past few years have seen considerable advances in treatment for lung cancer, yet the prognosis remains low. Lung cancer causes symptoms that come up late in the course of the disease and assessments are complicated. This means that half of the patients have a spread disease at diagnosis.

Early detection and prevention are the best strategies to improve the treatment outcome or eliminate the disease. People who smoke or have smoked have the greatest risk of lung cancer, though lung cancer also increasingly occurs in people who have never smoked. Lung cancer in never-smokers is a global rising concern and there is a fast growing need to understand how never-smokers’ disease differs from that of smokers, and how to effectively prevent and diagnose it early.

Vision Zero Cancer therefore invited participants ranging from current leading researchers in the field and clinicians to patient representatives and the medical industry to share experience and discoveries on how to develop an effective preventive strategy and opportunities for screening.

The meeting held around 30 participants and keynote speaker was Dr. Pan-Chyr Yang (MD, PhD, Chair Professor at the National Taiwan University Hospital and Academician of Academia Sinica, Taiwan). Dr. Yang shared the findings of the Taiwan Lung Cancer Screening for Never-Smoker Trial (TALENT), a nationwide lung cancer low-dose CT screening study focused on never-smokers which also aims to develop an effective strategy for screening of lung cancer in never-smokers and establish a risk prediction model to identify high-risk population that may benefit from low-dose CT screening.  In Taiwan, lung cancer is the leading cause of cancer mortality, and 53% of those who have died of lung cancer were never-smokers. The US National Lung Cancer Screening Trial (NLCST) and the Dutch NELSON trials demonstrated that the use of low-dose CT is effective for lung cancer screening; however, most of the lung cancer screenings focused on heavy smokers.

Of the 12,011 individuals included in the trial, the prevalence of lung cancer was 3.2% and 2.0% in participants with and without lung cancer family history, respectively. As explained during the meeting by Dr. Yang, 96.5% of the detected patients were stage 0 or 1 and potentially curable by surgery. The study also demonstrated the high risk of family history, especially among participants with a first-degree family history of lung cancer.The meeting further contained a panel discussion where Andrew Kaufman (MD, Associate Professor, thoracic surgeon at Mount Sinai Hospital in New York City) Kersti Oselin (MD, PhD, Medical Oncologist, North-Estonian Regional Hospital Cancer Center) Marcela Ewing (MD, PhD, Specialist Oncology and General Medicine, Sahlgrenska Academy, Regional Lead Early Detection of Cancer, Confederation of Regional Cancer Centres) Mattias Johansson (PhD, Scientist, Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), World Health Organization) and Mikael Johansson (MD, Associate Professor, Senior Consultant Oncology, Umeå University Hospital and Senior lecturer at Umeå University, Chair of the National Working Group for Lung Cancer Care) together with Dr. Pan-Chyr Yang elaborated their thoughts on the findings of the TALENT-study and how this relates to what they are facing in their current work.

Andrew Kaufman who is the leader of the never-smoking initiative at Mount Sinai Hospital, New York, reflected that caring for never-smoking lung cancer patients comes down to the intersection between epidemiology, biology, clinical capability, precision medicine, surgical care and all other clinical attributes available. He put emphasis on that it takes a multidisciplinary approach to look at the data and find out what is the substrate we are dealing with in terms of a clinical population, while also stating that for most cancers unfortunately the time for best intervention is at an asymptomatic time point. Dr. Kaufman continued by being hopeful that discussions like the one this meeting facilitated will shed light on and give direction to find the right thread to start pulling on to make a difference in the case of lung cancer. By learning from the important findings of Dr. Yangs work we will be able to provide ways to be smarter at identifying patients at risk yet also not increasing the costs of the inefficiency of care.

The various competent outlooks and insights presented by the panel gave a good transition to the last part of the meeting where Mattias Johansson from the Genetic Epidemiology Group at the WHO International Agency for Research on Cancer (IARC) presented a proof on concept study on the use of biomarkers to improve early detection and the possibilities this presents to detect more lung cancer patients in time. Medical oncologist Kersti Oselin from the North-Estonian Regional Hospital Cancer Center gave insights on AI for early detection and the prognostic significance of genomic markers in lung cancer recurrence. Rounding up the meeting from London Amied Shamaan, director within AI and clinical collaboration presented the work of a collaboration between Oxford University and GE Healthcare with other industry partners in a consortium that is formed around lung cancer screening and innovation and goes under the name of  The Integration and Analysis of Data using Artificial Intelligence to Improve Patient Outcomes with Thoracic Diseases (DART). The consortium has come together to be agile around the lung cancer screening process in the UK to provide innovation in technology and to be able to involve and better affect the patient population.

During the autumn follow-up meetings will be held to dig deeper into the common areas and challenges facing early detection of never smokers. Leveraging clearly on the consensus of the meeting around the need to gather across professions and sectors to build momentum around who and how to find never-smoking lung cancer patients at the right time. 

Watch the recording of the meeting.

Meeting agenda Följ länk

The purpose of this meeting was to share discoveries and experience on how to develop an effective preventive strategy.

How do we detect cancer earlier?

The earlier cancer is detected, the greater are the chances of survival. With new systems and knowledge, we can pick up on symptoms earlier and more quickly come to treatment. And get more chances to reach the vision of zero people dying from cancer and more people living longer and better.

Early detection and diagnosis
Follow link

Estonia-Sweden workshop on cancer – improving health outcomes through innovation and collaboration

The aim of Europe’s Beating Cancer Plan is to tackle the entire disease pathway. Over the coming years, it will focus on research and innovation, tap into the potential that digitalisation and new technologies offer, and mobilise financial instruments to support Member States. With its policy objectives, supported by ten flagship initiatives and multiple supporting actions, the Cancer Plan will help Member States turn the tide against cancer. Sweden and Estonia have decided to join forces in this endeavour.

On the 26th of May North Estonia Medical Centre Regionaal Haigla and Vision Zero Cancer arranged an interactive meeting to share experience and explore areas for collaboration in research and innovation to deliver on the mission of beating cancer. The meeting was focused around five key areas presented after the shared introduction by Dr. Terje Peetso (MD, Member of the Board at North Estonia Medical Centre) and Ebba Hallersjö Hult (Head of Vision Zero Cancer).

Bettina Ryll (MD, PhD, member of the Horizon Europe Mission Board for Cancer, Chair ESMO Patient Advocacy Group, Founder Melanoma Patient Network Europe) shared her thoughts on the emergence of A new era in cancer care in Europe followed by Professor Hans Hägglund (MD, Professor, National Cancer Coordinator, Chairman of the Federation of Regional Cancer centres, Chairman of Vision Zero Cancer) who painted the picture of the Swedish setting of 10 years with a national strategy – achievements and future outlook complemented by Dr. Vahur Valvere (MD, PhD, Director of Research and Development, North-Estonian Regional Hospital Cancer Center, Chairman of the Board of Estonian Cancer Society) giving the outlook of the Estonian National Cancer Control Plan for 2021-2030.

Mia Rajalin (PhD., lic. psychologist, Director of Studies, Region Stockholm, Member of the Board, the Swedish Lung Cancer Association and Vision Zero Cancer) member of the Vision Zero Cancer core-team and lung cancer patient gave her story of how the diagnosis became a driver for improving cancer care. The case of lung cancer was further elaborated by Dr. Simon Ekman (MD, PhD, Associate Professor, Senior Consultant, Department of Oncology-pathology, Karolinska University Hospital and Karolinska Institutet) and Dr. Kersti Oselin (MD, PhD, Medical Oncologist, North-Estonian Regional Hospital Cancer Center) sharing experiences from the Swedish Precision treatment of lung cancer at Karolinska Comprehensive Cancer Center and Estonian work with AI for early detection and prognostic significance of genomic markers in lung cancer recurrence.

Anu Planken (MD, PhD, Medical Oncologist, North-Estonian Regional Hospital Cancer Center) presented an Overview of the personalised oncology landscape in Estonia building on the promise of personalized medicine for cancer prevention, diagnosis and treatment.  Complementing this with the perspective of data and information-sharing Arvid Widenlou Nordmark (Coordinator National Quality Registries for Cancer, Confederation of Regional Cancer Centres) gave the Swedish view of how national quality registries are used to guide and evaluate clinical improvement efforts and introduced the The Patient Overview – an enabler for personalised medicine. Rounding up the group of speakers was Dr. Indrek Seire (MD, Surgical Oncologist, North-Estonian Regional Hospital Cancer Center) giving an oversight of the Estonian work with Structured health data and site-based databases in oncology. 

The meeting continued with the approximately 25 participants being split into breakout groups discussing the question of how we can leverage the promise of personalised medicine (PM) for our patients and societies? with the goal of both sharing knowledge and insights while strengthening possibilities for successful international collaborations.

The successful outcome of the meeting has led to a deepened collaboration within cancer care between Sweden and Estonia with planned visits and experience exchanges on site in Sweden during the autumn 2021 and in Estonia in the spring of 2022.  

Watch the recorded meeting.

Meeting agenda Följ länk

North Estonia Medical Centre Regionaal Haigla and the Swedish Innovation Milieu Vision Zero Cancer held an interactive meeting to share experiences and explore areas for collaboration in research and innovation to deliver on the mission of beating cancer.

What we innovate

Fewer people shall get ill and die from cancer. For that to work, we need to think in new ways. Both in terms of developing new solutions and getting better at using what is available.

Five areas that need renewal
Follow link

This is Vision Zero Cancer

Vision Zero Cancer challenges the prevailing ecosystem and connects new ones. We are going to turn cancer from a deadly into a curable or chronic disease.

Who we are
Follow link

Lung cancer screening – what are the success factors in the UK?

Cervical cancer, colorectal cancer and breast cancer are examples of cancers that are often detected early through screening. It saves hundreds of lives every year. Can screening work for lung cancer? The UK has tested. To learn from their projects, results and thoughts, we met in a digital conversation.

To improve early cancer diagnosis, outcomes and care for patients, Sweden is looking into the potential of introducing a national screening program for lung cancer. The UK has already carried out several projects and studies on lung cancer screening. At the end of September, we got to share their lessons from healthcare, universities and medical technology companies, as part of the work to see if a national screening program for lung cancer can fit into the Swedish context.

Dr. Philip Crosbie, Manchester University, shared words about a project in Manchester where they came to the realization, through a survey, that patients found it impractical to visit the clinic. Therefore, they introduced a screening bus to take the service directly to the patient.

Professor David Baldwin, of the East Midlands Cancer Alliance, told us how they found and contacted hard-to-reach patients – a combination of mobile screening and phone contact. He emphasized governing protocols as a prerequisite for uniform and standardized care. Baldwin also highlighted the importance of advisory committees and learning from each other.

Another UK project, in which the National Health Service, Oxford University and actors from the life science industry work together, is exploring how AI can diagnose lung cancer more accurately and quickly. And at the same time reduce the amount of invasive procedures. Algorithms become health care.

Professor Annie Mackie, Public Health England, described how the UK envisions a national screening programme for lung cancer. Now, with more evidence from published studies in the Netherlands and the US showing that targeted screening is effective against lung cancer, they are discussing a policy change – but there are still a lot of questions that need answers. How to choose which people to screen? Which ethical considerations must be taken? How will the screening be built up?

The Swedish researcher Mattias Johansson shared a research group’s work at the International Agency for Research on Cancer using biomarkers as a model to find the right patients. For example, if the screening only involves smokers, a large group of patients are overlooked. The future goal is to be able to predict risks using proteins, as a complement to risks detected via questionnaires.

The success factors from the UK can be summed up by the facts that care should be available to the needs of the citizen and the patient, that collaboration between clinics, research and other stakeholders is needed, and that digital tools can make healthcare more efficient. Lung cancer screening works, but must be properly implemented to deliver results, be effective and save lives.

More about the workshop

The experience exchange agenda Följ länk

Experiences of lung cancer screening studies, potential new technologies for early detection and the UK National Screening committee views on a population screening programme for lung cancer.

The participants in the experience exchange Följ länk

Experts from Great Britain and Sweden met online.

How do we detect cancer earlier?

The earlier cancer is detected, the greater are the chances of survival. With new systems and knowledge, we can pick up on symptoms earlier and more quickly come to treatment. And get more chances to reach vision zero.

Early detection and diagnosis
Follow link